{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:06:47Z","timestamp":1766081207207,"version":"3.48.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC2407403"],"award-info":[{"award-number":["2022YFC2407403"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Capital's Funds for Health Improvement and Research","award":["CFH 2022-2-5021; 2024-4-5026"],"award-info":[{"award-number":["CFH 2022-2-5021; 2024-4-5026"]}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20230484372"],"award-info":[{"award-number":["20230484372"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["L242144"],"award-info":[{"award-number":["L242144"]}]},{"name":"Young Elite Scientists Sponsorship Program by CAST","award":["2023QNRC001"],"award-info":[{"award-number":["2023QNRC001"]}]},{"name":"Young Elite Scientists Sponsorship Program by BAST","award":["No.BYESS2024001"],"award-info":[{"award-number":["No.BYESS2024001"]}]},{"name":"Autonomous Region Key R&D Program of China","award":["2022B03005-2"],"award-info":[{"award-number":["2022B03005-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12072-025-10818-2","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T09:26:39Z","timestamp":1744017999000},"page":"1428-1443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diverse approaches and sources to derive antitumor T cell for liver cancer: a single-cell sequence based research"],"prefix":"10.1007","volume":"19","author":[{"given":"Ai-xian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7933-7850","authenticated-orcid":false,"given":"Ming-gen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"3","key":"10818_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10818_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jncc.2020.12.001","volume":"1","author":"S Zhang","year":"2021","unstructured":"Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015. J Natl Cancer Center. 2021;1(1):2\u201311","journal-title":"J Natl Cancer Center"},{"issue":"15","key":"10818_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u20131462","journal-title":"N Engl J Med"},{"issue":"1","key":"10818_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen KY, Zhu Y, Xie SZ, et al. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17(1):25","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10818_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236","journal-title":"J Hepatol"},{"issue":"10204","key":"10818_CR6","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145\u20131158","journal-title":"Lancet"},{"issue":"2","key":"10818_CR7","first-page":"198","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10818_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.7150\/ijms.50883","volume":"18","author":"Y Tang","year":"2021","unstructured":"Tang Y, Wang L, Teng F, et al. The clinical characteristics and prognostic factors of combined hepatocellular carcinoma and cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma after surgical resection: a propensity score matching analysis. Int J Med Sci. 2021;18(1):187\u2013198","journal-title":"Int J Med Sci"},{"issue":"36","key":"10818_CR9","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.20.02672","volume":"38","author":"JD Gordan","year":"2020","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(36):4317\u20134345","journal-title":"J Clin Oncol"},{"issue":"1","key":"10818_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396","journal-title":"Ann Surg"},{"issue":"3","key":"10818_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/jso.25331","volume":"119","author":"G Spolverato","year":"2019","unstructured":"Spolverato G, Bagante F, Tsilimigras D, et al. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: a population-based analysis. J Surg Oncol. 2019;119(3):278\u2013287","journal-title":"J Surg Oncol"},{"issue":"10","key":"10818_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10818_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/liv.14086","volume":"39","author":"A Forner","year":"2019","unstructured":"Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98\u2013107","journal-title":"Liver Int"},{"issue":"1","key":"10818_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12876-016-0527-z","volume":"16","author":"KJ Yao","year":"2016","unstructured":"Yao KJ, Jabbour S, Parekh N, et al. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016;16(1):117","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10818_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40880-016-0146-7","volume":"35","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Yu WL, Lu XY, et al. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study. Chin J Cancer. 2016;35(1):82","journal-title":"Chin J Cancer"},{"issue":"2","key":"10818_CR16","volume":"1","author":"M Feng","year":"2020","unstructured":"Feng M, Pan Y, Kong R, et al. Therapy of primary liver cancer. Innovation (Cambridge). 2020;1(2): 100032","journal-title":"Innovation (Cambridge)"},{"issue":"9","key":"10818_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/d41573-022-00095-1","volume":"21","author":"AR Saez-Iba\u00f1ez","year":"2022","unstructured":"Saez-Iba\u00f1ez AR, Upadhaya S, Partridge T, et al. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022;21(9):631\u2013632","journal-title":"Nat Rev Drug Discov"},{"issue":"6230","key":"10818_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62\u201368","journal-title":"Science"},{"issue":"19","key":"10818_CR19","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2017.15218","volume":"318","author":"PB Bach","year":"2017","unstructured":"Bach PB, Giralt SA, Saltz LB. FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA. 2017;318(19):1861\u20131862","journal-title":"JAMA"},{"issue":"7","key":"10818_CR20","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, et al. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700","journal-title":"Sci Adv"},{"issue":"25","key":"10818_CR21","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676\u20131680","journal-title":"N Engl J Med"},{"issue":"1","key":"10818_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-024-00506-6","volume":"13","author":"MY Xu","year":"2024","unstructured":"Xu MY, Zeng N, Liu CQ, et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol. 2024;13(1):47","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"10818_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10214","volume":"6","author":"LL Wang","year":"2021","unstructured":"Wang LL, Janes ME, Kumbhojkar N, et al. Cell therapies in the clinic. Bioeng Transl Med. 2021;6(2): e10214","journal-title":"Bioeng Transl Med"},{"key":"10818_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","volume":"37","author":"S Guedan","year":"2019","unstructured":"Guedan S, Ruella M, June CH. Emerging cellular therapies for cancer. Annu Rev Immunol. 2019;37:145\u2013171","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10818_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/imm.13677","volume":"170","author":"D Wu","year":"2023","unstructured":"Wu D, Li Y. Application of adoptive cell therapy in hepatocellular carcinoma. Immunology. 2023;170(4):453\u2013469","journal-title":"Immunology"},{"issue":"2","key":"10818_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42(2):293\u2013304","journal-title":"Nat Biotechnol"},{"key":"10818_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12688\/f1000research.22139.1","volume":"9","author":"N Borcherding","year":"2020","unstructured":"Borcherding N, Bormann NL, Kraus G. scRepertoire: an R-based toolkit for single-cell immune receptor analysis. F1000Res. 2020;9:47","journal-title":"F1000Res"},{"issue":"6282","key":"10818_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189\u2013196","journal-title":"Science"},{"issue":"2","key":"10818_CR29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ymthe.2020.11.028","volume":"29","author":"X Li","year":"2021","unstructured":"Li X, Guo X, Zhu Y, et al. Single-cell transcriptomic analysis reveals BCMA CAR-T cell dynamics in a patient with refractory primary plasma cell Leukemia. Mol Ther. 2021;29(2):645\u2013657","journal-title":"Mol Ther"},{"issue":"11","key":"10818_CR30","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti M, Albukhari A, Alsaadi A, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124(11):1759\u20131776","journal-title":"Br J Cancer"},{"issue":"1","key":"10818_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12967-024-05206-7","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Zheng Y, Liu T, et al. The potential and promise for clinical application of adoptive T cell therapy in cancer. J Transl Med. 2024;22(1):413","journal-title":"J Transl Med"},{"key":"10818_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830292","volume":"13","author":"AE Andrea","year":"2022","unstructured":"Andrea AE, Chiron A, Mallah S, et al. Advances in CAR-T cell genetic engineering strategies to overcome hurdles in solid tumors treatment. Front Immunol. 2022;13: 830292","journal-title":"Front Immunol"},{"issue":"4","key":"10818_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1158\/2326-6066.CIR-18-0686","volume":"7","author":"W Lo","year":"2019","unstructured":"Lo W, Parkhurst M, Robbins PF, et al. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol Res. 2019;7(4):534\u2013543","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10818_CR34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537\u20131544","journal-title":"Blood"},{"issue":"7","key":"10818_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-002723","volume":"9","author":"K Kirtane","year":"2021","unstructured":"Kirtane K, Elmariah H, Chung CH, et al. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021;9(7):1","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10818_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-021-01339-1","volume":"20","author":"A Heine","year":"2021","unstructured":"Heine A, Juranek S, Brossart P. Clinical and immunological effects of mRNA vaccines in malignant diseases. Mol Cancer. 2021;20(1):52","journal-title":"Mol Cancer"},{"issue":"22","key":"10818_CR37","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang Q, Wu X, Wang Z, et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell. 2022;185(22):4049-4066.e4025","journal-title":"Cell"},{"issue":"1","key":"10818_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41392-023-01356-0","volume":"8","author":"E Yin","year":"2023","unstructured":"Yin E, Sun N, He J. Tumor-draining lymph node-derived tumor-specific memory CD8(+) T cells: a key player in PD-1\/PD-L1 immunotherapy. Signal Transduct Target Ther. 2023;8(1):111","journal-title":"Signal Transduct Target Ther"},{"key":"10818_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.isci.2019.11.005","volume":"22","author":"MJ O\u2019Melia","year":"2019","unstructured":"O\u2019Melia MJ, Lund AW, Thomas SN. The biophysics of lymphatic transport: engineering tools and immunological consequences. iScience. 2019;22:28\u201343","journal-title":"iScience"},{"issue":"1","key":"10818_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12967-022-03444-1","volume":"20","author":"K Okamura","year":"2022","unstructured":"Okamura K, Nagayama S, Tate T, et al. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. J Transl Med. 2022;20(1):241","journal-title":"J Transl Med"},{"issue":"6","key":"10818_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1588085","volume":"8","author":"T Matsuda","year":"2019","unstructured":"Matsuda T, Miyauchi E, Hsu YW, et al. TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. Oncoimmunology. 2019;8(6): e1588085","journal-title":"Oncoimmunology"},{"issue":"1","key":"10818_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2023-008026","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhu T, Shi Q, et al. Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy. J Immunother Cancer. 2024;12(1):1","journal-title":"J Immunother Cancer"},{"issue":"5\u20136","key":"10818_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10585-018-9927-5","volume":"35","author":"S Saha","year":"2018","unstructured":"Saha S, Elgamal M, Cherry M, et al. Challenging the conventional treatment of colon cancer by sentinel lymph node mapping and its role of detecting micrometastases for adjuvant chemotherapy. Clin Exp Metastasis. 2018;35(5\u20136):463\u2013469","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"10818_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska N, Cardenas MA, Valanparambil RM, et al. CD8(+) T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. 2023;56(1):107-124.e105","journal-title":"Immunity"},{"issue":"6","key":"10818_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciimmunol.aai8593","volume":"1","author":"T Wu","year":"2016","unstructured":"Wu T, Ji Y, Moseman EA, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. 2016;1(6):1","journal-title":"Sci Immunol"},{"issue":"8","key":"10818_CR46","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","volume":"41","author":"P Meiser","year":"2023","unstructured":"Meiser P, Knolle MA, Hirschberger A, et al. A distinct stimulatory cDC1 subpopulation amplifies CD8(+) T cell responses in tumors for protective anti-cancer immunity. Cancer Cell. 2023;41(8):1498-1515.e1410","journal-title":"Cancer Cell"},{"issue":"5","key":"10818_CR47","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, van Gulijk M, Mulder EE, et al. The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell. 2020;38(5):685-700.e688","journal-title":"Cancer Cell"},{"issue":"563","key":"10818_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aay3575","volume":"12","author":"DM Francis","year":"2020","unstructured":"Francis DM, Manspeaker MP, Schudel A, et al. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci Transl Med. 2020;12(563):1","journal-title":"Sci Transl Med"},{"issue":"2","key":"10818_CR49","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.biomaterials.2013.10.003","volume":"35","author":"SN Thomas","year":"2014","unstructured":"Thomas SN, Vokali E, Lund AW, et al. Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials. 2014;35(2):814\u2013824","journal-title":"Biomaterials"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10818-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10818-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10818-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:01:55Z","timestamp":1766080915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10818-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10818"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10818-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent for publication of their clinical details was obtained from every patient. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was approved by the Ethics Committee of Chinese PLA General Hospital (No. 2024-333).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}